Drug Trial Radar · NCT06475989
Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer
Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
264
Planned (sponsor's estimate)
Start
Dec 27, 2024
Primary completion
Sep 30, 2030
Study completion Sep 30, 2030
Sponsor
- Lead sponsor
- ECOG-ACRIN Cancer Research GroupResearch network
- Sponsor type
- Research network
- First posted
- Jun 26, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase III trial compares the effect of cabozantinib versus combination dabrafenib and trametinib for the treatment of patients with differentiated thyroid cancer that does not respond to treatment (refractory) and which expresses a BRAF V600E mutation. Cabozantinib is in a class of medications called receptor tyrosine kinase inhibitors. It binds to and blocks the action of several enzymes which are often over-expressed in a variety of tumor cell types. This may help stop or slow the growth of tumor cells and blood vessels the tumor needs to survive. Dabrafenib is an enzyme inhibitor that binds to and inhibits the activity of a protein called B-raf, which may inhibit the proliferation of tumor cells which contain a mutated BRAF gene. Trametinib is also an enzyme inhibitor. It binds to and inhibits the activity of proteins called MEK 1 and 2, which play a key role in activating pathways that regulate cell growth. This may inhibit the growth of tumor cells mediated by these pathways. The usual approach for patients with thyroid cancer is targeted therapy with dabrafenib and trametinib. This trial may help researchers decide which treatment option (cabozantinib alone or dabrafenib in combination with trametinib) is safer and/or more effective in treating patients with refractory BRAF V600E-mutated differentiated thyroid cancer.
Conditions
- Refractory Differentiated Thyroid Gland Carcinoma
Interventions
Biospecimen CollectionProcedure
Undergo blood sample collection
CabozantinibDrug
Given PO
Computed TomographyProcedure
Undergo CT scan
DabrafenibDrug
Given PO
Magnetic Resonance ImagingProcedure
Undergo MRI
Questionnaire AdministrationOther
Ancillary study
TrametinibDrug
Given PO
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression free survival (PFS)Time frame: From randomization to radiographic progression of disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 or death from any cause, up to 5 years
Locations
307 sites in 1 country. Site status is shown where the registry gives one.
Anchorage Associates in Radiation Medicine
Anchorage, Alaska · Recruiting
Anchorage Radiation Therapy Center
Anchorage, Alaska · Suspended
Alaska Breast Care and Surgery LLC
Anchorage, Alaska · Recruiting
Alaska Oncology and Hematology LLC
Anchorage, Alaska · Recruiting
Alaska Women's Cancer Care
Anchorage, Alaska · Recruiting
Katmai Oncology Group
Anchorage, Alaska · Recruiting
Providence Alaska Medical Center
Anchorage, Alaska · Recruiting
Fairbanks Memorial Hospital
Fairbanks, Alaska · Recruiting
Mercy Hospital Fort Smith
Fort Smith, Arkansas · Recruiting
CARTI Cancer Center
Little Rock, Arkansas · Recruiting
Providence Saint Joseph Medical Center/Disney Family Cancer Center
Burbank, California · Recruiting
UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care
Irvine, California · Recruiting
Providence Queen of The Valley
Napa, California · Recruiting
UC Irvine Health/Chao Family Comprehensive Cancer Center
Orange, California · Recruiting
Stanford Cancer Institute Palo Alto
Palo Alto, California · Recruiting
Providence Medical Foundation - Santa Rosa
Santa Rosa, California · Recruiting
Providence Santa Rosa Memorial Hospital
Santa Rosa, California · Recruiting
UCHealth University of Colorado Hospital
Aurora, Colorado · Recruiting
UCHealth Highlands Ranch Hospital
Highlands Ranch, Colorado · Recruiting
Smilow Cancer Hospital-Derby Care Center
Derby, Connecticut · Recruiting
Smilow Cancer Hospital Care Center-Fairfield
Fairfield, Connecticut · Recruiting
Smilow Cancer Hospital Care Center at Glastonbury
Glastonbury, Connecticut · Recruiting
Smilow Cancer Hospital Care Center at Greenwich
Greenwich, Connecticut · Recruiting
Smilow Cancer Hospital Care Center - Guilford
Guilford, Connecticut · Recruiting
Smilow Cancer Hospital Care Center at Saint Francis
Hartford, Connecticut · Recruiting
Smilow Cancer Center/Yale-New Haven Hospital
New Haven, Connecticut · Recruiting
Yale University
New Haven, Connecticut · Recruiting
Yale-New Haven Hospital North Haven Medical Center
North Haven, Connecticut · Recruiting
Smilow Cancer Hospital Care Center at Long Ridge
Stamford, Connecticut · Recruiting
Smilow Cancer Hospital-Torrington Care Center
Torrington, Connecticut · Recruiting
Smilow Cancer Hospital Care Center-Trumbull
Trumbull, Connecticut · Recruiting
Smilow Cancer Hospital-Waterbury Care Center
Waterbury, Connecticut · Recruiting
Smilow Cancer Hospital Care Center - Waterford
Waterford, Connecticut · Recruiting
Holy Cross Hospital
Fort Lauderdale, Florida · Recruiting
Mayo Clinic in Florida
Jacksonville, Florida · Active not recruiting
Emory University Hospital Midtown
Atlanta, Georgia · Recruiting
Saint Alphonsus Cancer Care Center-Boise
Boise, Idaho · Recruiting
Saint Luke's Cancer Institute - Boise
Boise, Idaho · Recruiting
Saint Alphonsus Cancer Care Center-Caldwell
Caldwell, Idaho · Recruiting
Kootenai Health - Coeur d'Alene
Coeur d'Alene, Idaho · Recruiting
Showing 40 of 307 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.